VIP vs KPV: Research Comparison
A Side-By-Side Research Comparison Of VIP And KPV - two peptides studied for immune and inflammatory modulation. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| VIP | KPV | |
|---|---|---|
| Category | Immunity & Wellness | Healing & Recovery |
| Compound Class | 28-amino acid neuropeptide and hormone; member of secretin/glucagon superfamily | Tripeptide C-terminal fragment of alpha-MSH (melanocyte-stimulating hormone) |
| Evidence Tier | Investigational | Research Compound |
| Molecular Target | VPAC1 and VPAC2 receptors (VIP/PACAP receptors); cAMP/PKA signaling; vasodilation, bronchodilation, immune modulation, GI motility | MC1R / melanocortin receptors; NF-kB inhibition; reduces TNF-alpha, IL-1beta, IL-6 production; mucosal protection |
| Molecular Weight | 3325.8 Da | 342.43 Da |
| Amino Acid Sequence | HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2 | Lys-Pro-Val |
| CAS Number | 40077-57-4 | 67727-97-3 |
| Half-Life | ~1-2 minutes | ~1.5 hours |
| Studied For | ARDS / acute respiratory failure research, Pulmonary hypertension, Sarcoidosis treatment research, Erectile dysfunction (intracavernosal) | GI inflammation / IBD research, Ulcerative colitis models, Crohn's disease models, Skin inflammation |
About VIP
A vasodilating peptide hormone studied for lung disease; carries a notable low-blood-pressure risk.
Read The Full VIP MonographAbout KPV
A small anti-inflammatory peptide studied mainly in gut-inflammation models.
Read The Full KPV MonographKey Differences
- VIP is categorized under Immunity & Wellness, while KPV falls under Healing & Recovery.
- Evidence tier differs: VIP is classified as Investigational; KPV is classified as Research Compound.
- Reported half-life differs: VIP at ~1-2 minutes versus KPV at ~1.5 hours.
- Primary molecular target differs: VIP acts on VPAC1 and VPAC2 receptors (VIP/PACAP receptors); cAMP/PKA signaling; vasodilation, bronchodilation, immune modulation, GI motility; KPV acts on MC1R / melanocortin receptors; NF-kB inhibition; reduces TNF-alpha, IL-1beta, IL-6 production; mucosal protection.
Continue Researching
VIP · KPV · Compare Tool · Research Library
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.